Loading clinical trials...
Loading clinical trials...
This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium labelled prostate-specific membrane antigen ra...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
VA Greater Los Angeles Healthcare System
NCT05939414 · Oligometastatic Prostate Cancer (OMPC)
NCT06190899 · mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, and more
NCT05751941 · Prostate Cancer, Metastatic Prostate Cancer
NCT07225946 · Prostatic Neoplasms, Castration-Resistant
NCT07181161 · Metastatic Prostate Cancer
VA Greater Los Angeles Healthcare System
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions